Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6889106 | 0.99 | L3MBTL1 (0.33) | L3MBTL1ALDH1A1MAPK1KMT2ATDP1 | |
| SCHEMBL6889111 | 0.93 | L3MBTL1 (0.34) | L3MBTL1ALDH1A1MAPK1KMT2ATDP1 | |
| SCHEMBL6301516 | 0.92 | L3MBTL1 (0.33) | L3MBTL1ALDH1A1MAPK1KMT2ATDP1 | |
| SCHEMBL3239936 | 0.89 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL3242091 | 0.88 | LMNA (0.30) | TDP1 | |
| SCHEMBL2919493 | 0.88 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL3239950 | 0.88 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL3242102 | 0.87 | LMNA (0.31) | TDP1 | |
| SCHEMBL137086 | 0.87 | LMNA (0.31) | TDP1 | |
| SCHEMBL14655765 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174045-B2 | Benzopyrylium compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-2850078-B1 | BENZOPYRYLIUM COMPOUNDS | PIERCE BIOTECHNOLOGY INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20180002340-A1 | BENZOPYRYLIUM COMPOUNDS | PIERCE BIOTECHNOLOGY, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9676787-B2 | Benzopyrylium compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170152267-A9 | BENZOPYRYLIUM COMPOUNDS | DYOMICS GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| US-20150322078-A1 | BENZOPYRYLIUM COMPOUNDS | DYOMICS GMBH (DE) | 2015-11-12 | — | — | US | disclosed |
| EP-2850078-A1 | BENZOPYRYLIUM COMPOUNDS | Pierce Biotechnology, Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| WO-2014035712-A1 | BENZOPYRYLIUM COMPOUNDS | PIERCE BIOTECHNOLOGY, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-6924372-B2 | Benzopyrylo-polymethine-based hydrophilic markers | DYOMICS GMBH (DE) | 2005-08-02 | — | — | US | disclosed |
| US-20040162423-A1 | Benzopyrylo-polymethine-based hydrophilic markers | DYOMICS GMBH (DE) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152267-A9 | BENZOPYRYLIUM COMPOUNDS | PABPC4, SSBP1, RBBP5 | L3MBTL1 332/4885ALDH1A1 3082/4885MAPK1 3570/4885 |
| US-20150322078-A1 | BENZOPYRYLIUM COMPOUNDS | PABPC4, SSBP1, RBBP5 | L3MBTL1 332/4885ALDH1A1 3082/4885MAPK1 3570/4885 |
| US-10174045-B2 | Benzopyrylium compounds | PABPC4, SSBP1, RBBP5 | L3MBTL1 332/4885ALDH1A1 3082/4885MAPK1 3570/4885 |
| US-20180002340-A1 | BENZOPYRYLIUM COMPOUNDS | PABPC4, SSBP1, RBBP5 | L3MBTL1 332/4885ALDH1A1 3082/4885MAPK1 3570/4885 |
| US-20040162423-A1 | Benzopyrylo-polymethine-based hydrophilic markers | EPCAM, CD68, CD44 | L3MBTL1 3381/4885ALDH1A1 1820/4885MAPK1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.